LOS ANGELES, Oct. 31 /PRNewswire-FirstCall/ -- Response Genetics, Inc. (Nasdaq: RGDX) today announced its President and CEO, Kathleen Danenberg, will provide a business overview, including an update on its ERCC-1 molecular diagnostic gene expression test for cisplatin-based chemotherapy resistance, at the BIOCOM Investor Conference at the San Diego Marriot Del Mar in San Diego October 31 to November 2. Ms. Danenberg will present at 5:30 p.m. PT Thursday, Nov. 1.
The presentation will be made available by webcast and can be accessed on the Media page of Response Genetics' website at http://www.responsegenetics.com.
About Response Genetics, Inc.
Response Genetics, Inc. ("RGI") (Nasdaq: RGDX) is engaged in the research and development of pharmacogenomic cancer diagnostic tests based on its proprietary and patented technologies. RGI's technologies enable extraction and analysis of genetic information from genes derived from tumor samples stored as formalin-fixed and paraffin embedded specimens. RGI currently generates revenue primarily from the sales of its proprietary analytical pharmacogenomic testing services of clinical trial specimens to the pharmaceutical industry. The company was founded in 1999 and its principal headquarters are located in Los Angeles, California. For more information, please visit http://www.responsegenetics.com.
Forward Looking Statement Notice
Except for the historical information contained herein, this press release and the statements of representatives of Response Genetics, Inc. (the "Company") related thereto contain or may contain, among other things, certain forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties.
Such statements may include, without limitation, statements with respect to the Company's plans, objectives, projections, expectations and intentions, such as the ability of the Company to analyze cancer samples, the potential for using the results of this research to develop diagnostic tests for cancer, the usefulness of genetic information to tailor treatment to patients, its ERCC1 molecular diagnostic gene expression test for cisplatin-based chemotherapy resistance, and other statements identified by words such as "projects", "may", "could", "would", "should", "believes", "expects", "anticipates", "estimates", "intends", "plans" or similar expressions. These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities and Exchange Commission. Actual results, including, without limitation, actual sales results, if any, or the application of funds, may differ from those set forth in the forward-looking statements. These forward- looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control). The Company undertakes no obligation to publicly update forward- looking statements, whether because of new information, future events or otherwise, except as required by law.
|SOURCE Response Genetics, Inc.|
Copyright©2007 PR Newswire.
All rights reserved